This article presents a systematic review and meta-analysis protocol to evaluate the efficacy and safety of Liuhedan, a traditional Chinese medicine (TCM) formula, for treating cellulitis. Cellulitis, characterized by redness, warmth, swelling, and tenderness, is a significant global health burden, especially in the United States, with over 650,000 annual admissions and a cost of approximately $3.7 billion. Despite its long-standing use in China alongside western medicine, no systematic reviews have assessed Liuhedan’s effectiveness and safety, which this study aims to address.

Liuhedan consists of ingredients like raw rhubarb, cortex phellodendri, mint, bletilla, and radix angelicae, known for their ability to clear heat and toxins, reduce swelling and pain, and alleviate stasis and dampness. Its anti-inflammatory and immunomodulating properties make it a promising treatment for cellulitis. Additionally, Liuhedan has been used to treat acute pancreatitis, helping to reduce inflammation and improve clinical outcomes by lowering inflammatory markers.

Beyond cellulitis and pancreatitis, Liuhedan is also utilized for phlegmon, skin and soft tissue infections, and various infectious inflammatory diseases. This review aims to provide robust evidence for Liuhedan’s therapeutic benefits in clinical practice.